Dexamethasone%25252520in%25252520chronic%25252520itp

# Dexamethasone in Chronic ITP ## Overview Dexamethasone is a potent synthetic glucocorticoid with minimal mineralocorticoid activity. In Immune Thrombocytopenia (ITP), it is utilized for its rapid immunomodulatory effects, including suppression of macrophage phagocytosis of antibody-coated platelets and inhibition of autoantibody production. It is increasingly preferred over prednisone for initial therapy due to faster response times and potential for improved durability. ## Primary Indications First-line treatment of newly diagnosed ITP and management of refractory/chronic ITP flares. ## Adult Dosing **Standard Regimen:** 40 mg orally once daily for 4 consecutive days. **Repeat cycles:** May be repeated every 14–28 days depending on platelet response and clinical judgment. Up to 6 cycles may be administered before declaring treatment failure. ## Pediatric Dosing **Standard Regimen:** 40 mg/m²/day (max 40 mg/dose) orally for 4 days. Dosing should be verified against institutional protocols or current hematology guidelines (e.g., ASH guidelines), as pediatric dosing can vary significantly based on institutional preference. ## Dose Adjustments * **Hepatic Impairment:** No specific adjustment; however, monitor closely as clearance may be altered. * **Renal Impairment:** No adjustment required. * **Concomitant medications:** Doses may require adjustment when co-administered with strong CYP3A4 inducers or inhibitors. ## Contraindications * Systemic fungal infections. * Known hypersensitivity to corticosteroids. * Recent live virus vaccination (administration is often held during steroid therapy). ## Adverse Effects * **Common:** Insomnia, mood disturbances (euphoria or depression), hyperglycemia, increased appetite, fluid retention/edema, and epigastric discomfort. * **Serious:** Increased risk of infection, gastrointestinal ulceration/perforation, hypertension, osteoporosis (long-term), and avascular necrosis. ## Key Drug Interactions * **CYP3A4 Inducers (e.g., Rifampin, Phenytoin, Carbamazepine):** Decrease dexamethasone efficacy. * **CYP3A4 Inhibitors (e.g., Ritonavir, Clarithromycin, Ketoconazole):** Increase dexamethasone serum concentrations and risk of toxicity. * **NSAIDs/Aspirin:** Increased risk of peptic ulcer disease and GI bleeding. * **Antidiabetic agents:** Dexamethasone induces hyperglycemia, potentially requiring increased doses of insulin or oral hypoglycemics. ## Monitoring * **Baseline:** Complete blood count (CBC) with differential, fasting blood glucose, blood pressure, and mental health screening. * **Ongoing:** Monitor platelet counts (weekly or as clinically indicated), glucose levels (especially in patients with diabetes), and signs of infection or GI distress. ## Clinical Pearls * **Administration:** Administer with food to mitigate GI irritation. * **Dexamethasone vs. Prednisone:** Dexamethasone is often favored in ITP for its shorter treatment course and lower risk of traditional "steroid face" and other chronic side effects associated with prolonged prednisone tapers. * **Steroid Response:** If no platelet response occurs after 6 cycles of dexamethasone, the patient is generally considered steroid-refractory, and second-line therapies (e.g., TPO-RAs, Rituximab, or Splenectomy) should be considered. * **Consultation:** Always refer to specific institutional hematology guidelines, as the number and frequency of pulse doses may vary based on local practice. *** *Educational Disclaimer: This information is for educational purposes only and does not constitute medical advice. Please consult current clinical guidelines, the hospital formulary, and the prescribing information (package insert) before administering any medication.*